Quantcast
Last updated on April 16, 2014 at 13:35 EDT

Latest colitis Stories

2013-07-30 23:27:09

Achieve Clinical Research is conducting a randomized clinical study to evaluate the safety, tolerability, and efficacy of a new drug in subjects with moderate to severe Ulcerative Colitis Birmingham, Alabama (PRWEB) July 30, 2013 *To see if you qualify for this Ulcerative Colitis Clinical Trial in Alabama, visit Achieve Clinical Research on the web (http://www.achieveclinical.com) or contact us directly at (205) 380-6434. There is no cost to participate, no insurance is required, and you...

2013-07-03 11:07:47

A new study indicates that aerobic exercise can lessen – or worsen – the symptoms of inflammatory bowel diseases such as ulcerative colitis, depending on the circumstances under which the exercise is undertaken. The researchers found that, in contrast to their sedentary peers, mice allowed to run freely on an exercise wheel for six weeks had fewer symptoms of colitis after exposure to a chemical agent that induces colitis symptoms in mice. However, mice...

2013-06-25 19:10:06

Researchers from UH Rainbow Babies & Children's Hospital report reasons behind the increase are unclear The largest investigation to date has found a dramatic increase in the number of hospitalizations for children with inflammatory bowel disease (IBD) during the past decade in the United States. The new study, published online and scheduled for the August 2013 print issue of the Journal of Investigative Medicine, found a 65 percent increase in IBD hospital discharges from 2000 to...

2013-06-21 23:04:27

Bridgestone Retail Operations Customer Round-Up Campaign Supports the Crohn’s & Colitis Foundation of America Bala Cynwyd, PA (PRWEB) June 21, 2013 The Crohn’s & Colitis Foundation of America (CCFA) is delighted to announce that for the months of July and August, Bridgestone Retail Operations, LLC (BRSO) will raise money for Crohn’s disease and ulcerative colitis with a nationwide “round-up” program. BSRO employees and its 2,200 retail locations nationwide, including...

2013-06-21 08:24:56

DEERFIELD, Ill. and OSAKA, Japan, June 21, 2013 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that a Biologics License Application (BLA) has been submitted to the United States (U.S.) Food and Drug Administration (FDA) for vedolizumab, an investigational humanized monoclonal antibody for the treatment of adults with moderately to severely active Crohn's disease (CD) and ulcerative...

2013-06-14 23:04:28

Run Takes Place on August 18th--Sign-up Today (PRWEB) June 14, 2013 Attention: Assignment Editors/Event Producers June 13, 2013              WHAT:             Philadelphia/Delaware Valley Chapter of the Crohn´s &     Colitis Foundation´s 20th annual Guts & Glory 5K Run...

2013-06-05 08:28:50

The role of gut bacteria in ulcerative colitis to be the focus of pharmaceutical collaboration in microbiome R&D SAN BRUNO, Calif., June 5, 2013 /PRNewswire/ -- Second Genome, Inc. announced today that the company has entered into an agreement with Janssen Biotech, Inc. (Janssen) focused on microbiome drug discovery. With the goal of advancing novel drug targets, the agreement is focused on therapeutic mechanisms in ulcerative colitis mediated by the bacterial ecosystem living...

2013-05-02 08:39:04

For the Treatment of Severe Ulcerative Colitis, Remicade Holds a Strong Lead Over Humira, According to a New Report from BioTrends Research Group EXTON, Pa., May 2, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that Janssen/Merck/Mitsubishi Tanabe's Remicade is the market leader for the treatment of ulcerative colitis in the EU5 (France, Germany, Italy, Spain and the United...

2013-04-15 23:00:43

Annual CCFA Spring Patient Education Day at Thomas Jefferson Hospital On Sunday, April 28, 2013. Philadelphia, PA (PRWEB) April 15, 2013 On Sunday, April 28, 2013, the Philadelphia/Delaware Valley Chapter of the Crohn´s & Colitis Foundation of America (CCFA) will proudly hold the Annual Spring Patient Education Day at Thomas Jefferson Hospital. This free program provides a supportive environment for patients, families and caregivers to learn about Crohn's disease and ulcerative...

2013-04-10 04:21:10

HEIDELBERG, Germany, April 10, 2013 /PRNewswire/ -- IND paves the way for the US element of a global Phase III development program with LT-02 in conjunction with European licensee Dr. Falk Pharma GmbH, whose pivotal study will start in Q4 2013 Lipid Therapeutics announces today that it has successfully filed its first US IND for its lead product LT-02 and is now in a position to proceed with a planned Phase III trial in the US in...


Latest colitis Reference Libraries

0_9f897835bb09adc2a84fda23893d87f8
2011-04-15 13:50:01

Clostridium difficile, also known as "CDF/cdf", or "C. diff", is a Gram-positive bacteria of the genus Clostridium that causes severe diarrhea and other intestinal disease when competing bacteria in the gut flora are wiped out by antibiotics. They are anaerobic, spore-forming rods and is the most serious cause of antibiotic-associated diarrhea and potentially to pseudomembranous colitis. C. difficile bacteria naturally resides in the gut of a small percentage of the adult population. Others...

More Articles (1 articles) »